Andere talen Cessatech A/S

Aandelen

CESSA

DK0061411964

slotkoers NORDIC GROWTH MARKET Andere beurzen 00:00:00 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,3 ^DKK	0,00%		+3,96%	-13,22%

29/02	Cessatech A/S rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
2023	Cessatech A/S rapporteert resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

A short business update	18/04
Minutes from the Annual General Meeting in Cessatech A/S	27/03
Annual General Meeting - 27 March 2024	11/03
Cessatech A/S publishes Annual Report for the fiscal year 2023	29/02
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2	30/01
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024	23/01
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2	22/01
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2	12/01
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD	11/01
Q&A session related topline data Study 0205	04/01
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001	22/12
Third Quarter Report Q3-2023	16/11
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	16/11
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children	25-10-23
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	25-10-23
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001	21-09-23
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	21-09-23
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%	12-09-23
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children	12-09-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cessatech A/S

Aandelen

CESSA

DK0061411964

Andere talen

Filters